Page last updated: 2024-11-07

spironolactone and Hirsutism

spironolactone has been researched along with Hirsutism in 160 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.

Research Excerpts

ExcerptRelevanceReference
"Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations."9.41Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023)
"We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)."9.24Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017)
"The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)."9.22Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016)
" It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone."9.19In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014)
"A total of 134 women with moderate and severe hirsutism were randomly assigned to three treatment regimens: Group I received 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA) (n = 45); group II received 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone (n = 44); and group III received 35 μg of EE/2 mg of CPA plus 100 mg of CPA (n = 45), daily for 6 months."9.16Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. ( Gul, S; Kelekci, KH; Kelekci, S; Yengel, I; Yilmaz, B, 2012)
" Twenty-nine women with hirsutism as a consequence of PCOS or idiopathic hirsutism were randomly assigned to receive 250 mg/day flutamide alone or 100 mg/day spironolactone plus a combination tablet of 2 mg CPA/35 microg EE, for 6 months."9.13Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. ( Aral, Y; Bavbek, N; Culha, C; Demirbas, B; Güler, S; Karakurt, F; Sahin, I; Serter, R, 2008)
"To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism."9.11A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. ( Bayram, F; Everest, H; Keleştimur, F; Sahin, Y; Unlühizarci, K, 2004)
"To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)."9.11Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005)
"To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism."9.10Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. ( Lumachi, F; Rondinone, R, 2003)
"The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone alone, in patients with hirsutism."9.10Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. ( Kirim, S; Sert, M; Tetiker, T, 2003)
"To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months."9.09Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000)
"To study the effectiveness and safety of spironolactone in the treatment of hirsute women and of the association of spironolactone plus dexamethasone in the treatment of hirsutism with glucocorticoid sensitive hyperandrogenism."9.09[Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone]. ( Aravena, L; Devoto, E; Ríos, R, 2000)
"To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolactone, in the treatment of hirsutism."9.08Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S; Yücelten, D, 1996)
"To compare the efficacy of finasteride and spironolactone in the treatment of idiopathic hirsutism."9.08Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Yücelten, D, 1997)
"To compare the clinical efficacy and safety of Diane 35 (cyproterone acetate [2] mg and ethinyl estradiol [35 microg]) plus spironolactone [100 mg] combination and Diane 35 alone in the treatment of hirsutism."9.08Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. ( Keleştimur, F; Sahin, Y, 1998)
"To compare the efficacy of two antiandrogens, spironolactone and flutamide, in the treatment of hirsutism."9.07Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. ( Demirçay, Z; Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S, 1994)
"To compare the clinical efficacy and safety of the pure antiandrogen flutamide and the steroidal derivative spironolactone in the treatment of hirsutism in women."9.07Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, RR, 1994)
"The effect of spironolactone on female hirsutism was studied in 18 patients."9.05Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. ( Biffignandi, P; Manieri, C; Massucchetti, C; Messina, M; Molinatti, GM; Novi, RF, 1983)
"The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."8.85Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."8.82Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003)
"To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone."8.82Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."8.81Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."8.80Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000)
"Combined oral contraceptives (COC) and spironolactone are the first and second-line treatments of mild hirsutism, since the use of cyproterone acetate was restricted to the treatment of severe hirsutism by the French guidelines for hyperandrogenism published in May 2020."8.12[Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life]. ( Begon, E; Bernard, V; Grouthier, V; Hocke, C; Lefoulon, N; Perrissin-Fabert, M, 2022)
"Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome."7.78Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012)
"To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period."7.75Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009)
"The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne."7.68[Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990)
"Spironolactone (Aldactone), 100 mg to 200 mg daily, has antiandrogenic effects that may enhance treatment of androgen-excess syndromes, particularly severe hirsutism."7.68Use of spironolactone in treatment of hirsutism. ( Cumming, DC, 1990)
"The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone."7.67Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984)
"Sixteen women with hirsutism used spironolactone, 100 mg daily without interruption, plus norethindrone (1 mg) and ethinyl estradiol (35 mg) for 21 of each 28 days."7.67Spironolactone and estrogen-progestin therapy for hirsutism. ( Board, JA; Rosenberg, SM; Smeltzer, JS, 1987)
"Spironolactone (100 mg) for 25 days in each menstrual cycle was assessed over 6 months for treatment of hirsutism in 35 patients."7.67Spironolactone in the treatment of hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Hague, W; Jeffcoate, SL; Katz, M, 1986)
"The clinical efficacy of a combination of spironolactone and an oral contraceptive pill (Conova 30) was assessed in 23 patients presenting with hirsutism of whom 20 completed 6 months of treatment."7.67Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Jeffcoate, SL, 1985)
"The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome."7.66Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983)
"Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone."7.66Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982)
"Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day."7.66Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981)
"Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)."7.66Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981)
"After 8 months, hirsutism has improved in 24 (70."6.69[The treatment of hirsutism in adolescent girls with spironolactone]. ( Malinova, M, 1999)
"Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism."6.66Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020)
"Hirsutism was classified according to Lorenzo (1970)."6.37Treatment of hirsutism with spironolactone. ( Tremblay, RR, 1986)
"Spironolactone (SP) is a potassium sparing diuretic with antiandrogenic properties."5.62Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: ( Albash, R; Darwish, KM; El-Dahmy, RM; Fahmy, AM; Hamed, MIA, 2021)
"Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women."5.62Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021)
"Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile."5.56Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020)
"Spironolactone use as a treatment for hirsutism and other dermatological conditions among polycystic ovary syndrome (PCOS) and idiopathic hirsutism shows varied results."5.41Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis. ( Asrar, MM; Bashir, R; Ganie, MA; Shah, IA; Wani, IA, 2023)
"Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations."5.41Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023)
"Spironolactone was used in 90 hirsute women because of its antiandrogenic effect."5.27Spironolactone in the treatment of hirsutism. ( Akyürek, C; Köksal, A; Pabuçcu, R, 1987)
"Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome."5.27Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986)
"We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)."5.24Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017)
"While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism."5.22Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. ( Barbieri, JS; Bommareddy, K; Hamade, H; Lopez-Olivo, MA; Tosh, T; Wehner, M, 2022)
"The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)."5.22Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016)
" It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone."5.19In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014)
"A total of 134 women with moderate and severe hirsutism were randomly assigned to three treatment regimens: Group I received 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA) (n = 45); group II received 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone (n = 44); and group III received 35 μg of EE/2 mg of CPA plus 100 mg of CPA (n = 45), daily for 6 months."5.16Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. ( Gul, S; Kelekci, KH; Kelekci, S; Yengel, I; Yilmaz, B, 2012)
" Twenty-nine women with hirsutism as a consequence of PCOS or idiopathic hirsutism were randomly assigned to receive 250 mg/day flutamide alone or 100 mg/day spironolactone plus a combination tablet of 2 mg CPA/35 microg EE, for 6 months."5.13Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. ( Aral, Y; Bavbek, N; Culha, C; Demirbas, B; Güler, S; Karakurt, F; Sahin, I; Serter, R, 2008)
"To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism."5.11A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. ( Bayram, F; Everest, H; Keleştimur, F; Sahin, Y; Unlühizarci, K, 2004)
"To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)."5.11Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005)
"To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism."5.10Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. ( Lumachi, F; Rondinone, R, 2003)
"The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone alone, in patients with hirsutism."5.10Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. ( Kirim, S; Sert, M; Tetiker, T, 2003)
"Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day."5.09Recurrence rate of hirsutism after 3 different antiandrogen therapies. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Yücelten, D, 1999)
"To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months."5.09Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000)
"To assess the androgen-suppressing effect of spironolactone, and the use of this drug as a single agent in the long-term therapy of hirsute patients with either polycystic ovary syndrome (PCOS) or idiopathic hirsutism (IH)."5.09Spironolactone as a single agent for long-term therapy of hirsute patients. ( Lhullier, F; Lisboa, KO; Mattiello, S; Spritzer, PM, 2000)
"This study explored the effect of the anti-androgen spironolactone on sex-hormone binding globulin (SHBG) and the distribution of circulating testosterone (T) into various free and bound fractions in seven women with hirsutism assessed before and then monthly for three months on a regimen of spironolactone, 100 mg bid as the sole therapeutic agent."5.08The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. ( Kirschner, MA; Lerário, AC; Luthold, WW; Marcondes, JA; Mendonça, BB; Minanni, SL; Nery, M; Wajchenberg, BL, 1995)
"To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolactone, in the treatment of hirsutism."5.08Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S; Yücelten, D, 1996)
"To compare the clinical efficacy and safety of Diane 35 (cyproterone acetate [2] mg and ethinyl estradiol [35 microg]) plus spironolactone [100 mg] combination and Diane 35 alone in the treatment of hirsutism."5.08Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. ( Keleştimur, F; Sahin, Y, 1998)
"To compare the efficacy of two antiandrogens, spironolactone and flutamide, in the treatment of hirsutism."5.07Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. ( Demirçay, Z; Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S, 1994)
"To compare the clinical efficacy and safety of the pure antiandrogen flutamide and the steroidal derivative spironolactone in the treatment of hirsutism in women."5.07Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, RR, 1994)
"Because of its anti-androgenic activity spironolactone 50-200 mg daily is advocated widely for the management of female hirsutism but this practice lacks adequately controlled experimental support."5.06Lack of effect of spironolactone on hair shaft diameter in hirsute females. ( MacKie, R; McInnes, GT; McLellan, AR; Rentoul, J, 1989)
"The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."4.85Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009)
" A significant reduction in hirsutism was found for flutamide, spironolactone, cyproterone acetate combined with an oral contraceptive, thiazolidinediones, oral contraceptive pills (OCPs), finasteride and metformin but not for placebo."4.84A systematic review of commonly used medical treatments for hirsutism in women. ( Conway, GS; Koulouri, O, 2008)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."4.82Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003)
"To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone."4.82Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."4.81Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001)
"The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women."4.80Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000)
"Retrospective analysis of 63 women with hyperandrogenic skin symptoms due to polycystic ovary syndrome (PCOS), treated with spironolactone for at least 6 months as first-line treatment."4.31Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. ( Andrisani, A; Armanini, D; Barbot, M; Beggiao, F; Belloni Fortina, A; Bordin, L; Ceccato, F; Donà, G; Keiko Vedolin, C; Orlando, G; Ragazzi, E; Sabbadin, C; Scaroni, C, 2023)
"Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome."3.78Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012)
" 51 women completed a 6-month OCP trial (20 µg ethinyl estradiol + 75 µg gestodene, 21/28 days per cycle, plus 100 mg spironolactone in 32 women with moderate to severe hirsutism)."3.78Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. ( Maier, PS; Spritzer, PM, 2012)
"To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period."3.75Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009)
"Low-dose spironolactone improves hirsutism in a majority of hirsute women, irrespective of age, severity or duration of hirsutism, menstrual status, or serum hormone levels."3.68Predictors of clinical response in hirsute women treated with spironolactone. ( Crosby, PD; Rittmaster, RS, 1991)
"The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne."3.68[Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990)
"The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone."3.67Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984)
"Menstrual irregularity is a recognized side effect of spironolactone when used as a treatment for hirsutism in women."3.67Absence of progestational activity of oral spironolactone. ( Brumsted, JR; Gibson, M; Nakajima, ST; Riddick, DH, 1989)
"A survey of 54 patients taking spironolactone for hirsutes or acne showed that side-effects occurred in 91%; in 80% of patients, these were related to the anti-androgenic mechanism of the drug (menstrual disturbances, and breast enlargement and tenderness)."3.67Tolerance of spironolactone. ( Cunliffe, WJ; Hughes, BR, 1988)
"Sixteen women with hirsutism used spironolactone, 100 mg daily without interruption, plus norethindrone (1 mg) and ethinyl estradiol (35 mg) for 21 of each 28 days."3.67Spironolactone and estrogen-progestin therapy for hirsutism. ( Board, JA; Rosenberg, SM; Smeltzer, JS, 1987)
"Spironolactone and oral contraceptives have been used separately with some success in the treatment of hirsutism."3.67Prolonged suppression of hirsutism with combination therapy in an adolescent with insulin resistance and acanthosis nigricans. ( Moore, DC, 1987)
"Spironolactone (S) has been used successfully for the treatment of hirsutism."3.67The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. ( Brinton, D; Horton, R; Lobo, RA; Serafini, P; Shoupe, D, 1985)
"The clinical efficacy of a combination of spironolactone and an oral contraceptive pill (Conova 30) was assessed in 23 patients presenting with hirsutism of whom 20 completed 6 months of treatment."3.67Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Jeffcoate, SL, 1985)
"The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome."3.66Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983)
"Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone."3.66Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982)
"Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day."3.66Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981)
"Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)."3.66Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981)
"Minoxidil-induced sequential changes in plasma renin activity, urinary aldosterone and norepinephrine excretion were assessed in 11 patients with severe hypertension receiving propranolol or oxprenolol, chlorthalidone and spironolactone."3.66[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. ( Brunner, HR; Ferguson, RK; Gavras, H; Jaeger, P; Jéquier, E; Turini, GA, 1978)
"Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgenic effect."2.82Spironolactone in dermatology. ( Aguilar Medina, DA; Cazarín, J; Magaña, M, 2022)
"Polycystic ovary syndrome is the most common endocrinological problem associated with hirsutism."2.68Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. ( Gökmen, O; Gülekli, B; Işik, AZ; Senöz, S, 1996)
"Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism."2.66Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020)
" Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases."2.65Antiandrogens in the treatment of acne and hirsutism. ( Hammerstein, J; Moltz, L; Schwartz, U, 1983)
"Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female."2.61Hirsutism in Women. ( Bain, J; Matheson, E, 2019)
"Flutamide was more effective than placebo in two studies (MD -7·60, 95% CI: -10·53 to -4·67 and MD -7·20, 95% CI: -10·15 to -4·25), as was spironolactone (MD -7·69, 95% CI: -10·12 to -5·26)."2.53Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016)
"Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women."2.46Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010)
"In the treatment of hirsutism several options are now available, including pharmacologic regimens and cosmetic measures."2.46Medical Treatment of Hirsutism in Women ( Basso, SM; Lumachi, F, 2010)
"--Weight loss is an important part of the treatment of obese, hirsute women with PCOS."2.44[Hirsutism]. ( Pijl, H; van Zuuren, EJ, 2007)
"Although hirsutism and androgenetic alopecia are cosmetic problems, they can be psychologically devastating for women."2.40Antiandrogen treatment of polycystic ovary syndrome. ( Rittmaster, RS, 1999)
"Hirsutism was classified according to Lorenzo (1970)."2.37Treatment of hirsutism with spironolactone. ( Tremblay, RR, 1986)
" Such effects depend not only on increased androgen production by the ovary or adrenal gland but also on the bioavailability of androgen to peripheral tissues."2.37Anti-androgens in gynaecological practice. ( Franks, S; Reed, MJ, 1988)
"Acne is an off-label use of some COCs."1.72Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022)
"Spironolactone (SP) is a potassium sparing diuretic with antiandrogenic properties."1.62Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: ( Albash, R; Darwish, KM; El-Dahmy, RM; Fahmy, AM; Hamed, MIA, 2021)
"Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women."1.62Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021)
"Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile."1.56Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020)
"Successful treatment of hirsutism with combination OC+SPL requires at least 6 months of therapy, with the proportion of satisfied patients continuing to increase with treatment duration."1.48Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. ( Azziz, R; Ezeh, U; Huang, A; Landay, M, 2018)
"Polycystic ovary syndrome is the underlying cause in the vast majority of patients with hirsutism; however, it should be kept in mind that it can only be diagnosed after exclusion of some other diseases such as non-classical congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and acromegaly."1.39Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013)
"Pneumomediastinum is an uncommon disease arising most frequently and remains largely underdiagnosed clinically, especially in young, healthy patients."1.38Pneumomediastinum after retching. ( Al, B; Genc, S; Murat, Ç; Sanli, M; Yildirim, C; Zengin, S, 2012)
"Hirsutism is the manifestation of hyperandrogenemia in PCOS."1.32The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004)
"Cyproterone acetate has been used in Europe for many years, but in the United States it has only been approved as an orphan drug to treat severe hirsutism."1.28Antiandrogens in the treatment of acne and hirsutism. ( Jurzyk, RS; Rose, LI; Spielvogel, RL, 1992)
" We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone."1.28Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. ( Bedocs, NM; Bergfeld, W; Gidwani, GP; Gupta, MK; Parker, R; Redmond, GP; Skibinski, C, 1990)
" Cyproterone acetate allows differentiated treatment according to the various grades of hirsutism by modification of dosage and application."1.27[The concept of the causal therapy of hirsutism]. ( Schmidt, JB, 1986)
"Spironolactone was used in 90 hirsute women because of its antiandrogenic effect."1.27Spironolactone in the treatment of hirsutism. ( Akyürek, C; Köksal, A; Pabuçcu, R, 1987)
" In 11 women (68%), the dosage had to be decreased or the medication discontinued due to side-effects."1.27Side-effects of spironolactone therapy in the hirsute woman. ( Helfer, EL; Miller, JL; Rose, LI, 1988)
" One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA."1.27A comparative study of Aldactone and Diane in the treatment of hirsutism. ( Djøseland, O; Lunde, O, 1987)
"Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome."1.27Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986)
"The unbound fraction of plasma testosterone (T) can freely enter tissues, whereas the bioavailability of the albumin-bound T is controversial."1.27Bioavailability of albumin-bound testosterone. ( Bardin, CW; Cefalu, W; Manni, A; Nisula, BC; Pardridge, WM; Santen, RJ; Santner, SJ, 1985)
"Thirteen anovulatory oligomenorrheic, hyperandrogenic, and normoprolactinemic women were treated with spironolactone (aldactone) throughout six consecutive menstrual cycles in a dosage of 100 to 150 mg/day."1.26Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women. ( Diamant, YZ; Evron, S; Shapiro, G, 1981)

Research

Studies (160)

TimeframeStudies, this research(%)All Research%
pre-199066 (41.25)18.7374
1990's33 (20.63)18.2507
2000's28 (17.50)29.6817
2010's20 (12.50)24.3611
2020's13 (8.13)2.80

Authors

AuthorsStudies
Albash, R1
Fahmy, AM1
Hamed, MIA1
Darwish, KM1
El-Dahmy, RM1
Aguilar Medina, DA1
Cazarín, J1
Magaña, M1
Bommareddy, K1
Hamade, H1
Lopez-Olivo, MA1
Wehner, M1
Tosh, T1
Barbieri, JS1
Wilkinson, LD1
Brady, PH1
Gin, GT1
Rosenblum, E1
Sabbadin, C1
Beggiao, F1
Keiko Vedolin, C1
Orlando, G1
Ragazzi, E1
Ceccato, F1
Barbot, M1
Bordin, L1
Donà, G1
Andrisani, A1
Belloni Fortina, A1
Scaroni, C1
Armanini, D1
Lefoulon, N1
Begon, E1
Perrissin-Fabert, M1
Grouthier, V1
Hocke, C1
Bernard, V1
Bashir, R1
Asrar, MM1
Shah, IA1
Wani, IA1
Ganie, MA2
Zeng, H1
Zhang, Y1
Huang, S1
Wu, J1
Ren, W1
Zhou, L1
Huang, L1
Ye, Y1
Basu, P1
Elman, SA1
Abudu, B1
Beckles, A1
Salian, P1
Yanes, DA1
Porter, ML1
Reynolds, RV2
Vargas-Mora, P1
Morgado-Carrasco, D1
Heymann, WR1
Searle, TN1
Al-Niaimi, F1
Ali, FR1
Amer, RI1
Yassin, GE1
Mohamed, RA1
Fayez, AM1
Ibáñez, L1
Del Río, L1
Díaz, M1
Sebastiani, G1
Pozo, ÓJ1
López-Bermejo, A1
de Zegher, F1
Alpañés, M1
Álvarez-Blasco, F1
Fernández-Durán, E1
Luque-Ramírez, M1
Escobar-Morreale, HF1
Ezeh, U1
Huang, A1
Landay, M1
Azziz, R1
Azarchi, S1
Bienenfeld, A1
Lo Sicco, K1
Marchbein, S1
Shapiro, J1
Nagler, AR1
Matheson, E1
Bain, J1
Mazza, A1
Fruci, B1
Guzzi, P1
D'Orrico, B1
Malaguarnera, R1
Veltri, P1
Fava, A1
Belfiore, A1
Unluhizarci, K3
Karaca, Z2
Kelestimur, F7
Buzney, E1
Sheu, J1
Buzney, C1
van Zuuren, EJ3
Fedorowicz, Z2
Carter, B1
Pandis, N1
Diri, H1
Karaburgu, S1
Acmaz, B1
Tanriverdi, F1
Brown, J1
Farquhar, C4
Lee, O4
Toomath, R4
Jepson, RG1
Koulouri, O2
Conway, G1
Nakhjavani, M1
Hamidi, S1
Esteghamati, A1
Abbasi, M1
Nosratian-Jahromi, S1
Pasalar, P1
Bachelot, A1
Chabbert-Buffet, N1
Salenave, S1
Kerlan, V1
Galand-Portier, MB1
Artini, PG1
Di Berardino, OM1
Simi, G1
Papini, F1
Ruggiero, M1
Monteleone, P1
Cela, V1
Brodell, LA1
Mercurio, MG2
Lumachi, F2
Basso, SM1
Kelekci, KH1
Kelekci, S1
Yengel, I1
Gul, S1
Yilmaz, B1
Maier, PS2
Mattiello, SS1
Lages, L1
Spritzer, PM3
Kulshreshtha, B1
Gupta, N1
Ammini, AC1
Al, B1
Yildirim, C1
Zengin, S1
Murat, Ç1
Genc, S1
Sanli, M1
Amesse, LS1
Ding, X1
Pfaff-Amesse, T1
Unlühizarci K, K1
Everest, H2
Bayram, F2
Rondinone, R1
Sert, M1
Tetiker, T1
Kirim, S1
Jepson, R3
Ajossa, S1
Guerriero, S1
Paoletti, AM1
Orrù, M1
Melis, GB1
Sahin, Y3
Guzelmeric, K1
Seker, N1
Unal, O1
Turan, C1
Al-Inany, H1
Christy, NA1
Franks, AS1
Cross, LB1
Inal, MM1
Yildirim, Y1
Taner, CE1
Conway, GS1
Pijl, H1
Yildiz, BO1
Karakurt, F1
Sahin, I1
Güler, S1
Demirbas, B1
Culha, C1
Serter, R1
Aral, Y1
Bavbek, N1
Biffignandi, P3
Massucchetti, C2
Molinatti, GM5
Zaun, H1
Braithwaite, SS1
Jabamoni, R1
De Pedrini, P2
Suraci, C2
Costa, C2
Hammerstein, J1
Moltz, L1
Schwartz, U1
Shoupe, D2
Lobo, RA7
Belaube, P1
Devaux, J1
Gamby, T1
Garcin, G1
Privat, Y1
Messina, M1
Manieri, C1
Novi, RF1
Spandri, P1
Gangemi, M1
Nardelli, GB1
Meneghetti, G1
Grandesso, R1
De Salvia, D1
Ambrosio, GB1
Predebon, O1
Abramovici, Y1
Guillet, F1
Matte, R1
Chaieb, L1
Belanger, R1
Ylöstalo, P2
Hána, V1
Marek, J1
Gregorová, I1
Evron, S2
Shapiro, G2
Diamant, YZ1
Milewicz, A1
Silber, D1
Kirschner, MA3
Gamborg Nielsen, P1
Mitra, K1
Chaudhuri, N1
Kundu, D1
Mondal, S1
Ghose, D1
Baranowska, B1
Stopińska-Głuszak, U1
Niewiadomska, A1
Zgliczyński, S1
Cumming, DC2
Yang, JC1
Rebar, RW1
Yen, SS1
Blum, I2
Kaufman, H2
Marilus, R1
Rusecki, Y1
Chovers, I1
Bruhis, S1
Ross, HD1
Marcondes, JA1
Minanni, SL1
Luthold, WW1
Lerário, AC1
Nery, M1
Mendonça, BB1
Wajchenberg, BL1
Wong, IL1
Morris, RS1
Chang, L1
Spahn, MA1
Stanczyk, FZ1
Erenus, M5
Vĕtr, M2
Sobek, A1
McMullen, GR1
Van Herle, AJ1
Gürbüz, O4
Durmuşoğlu, F4
Demirçay, Z1
Pekin, S2
Cusan, L1
Dupont, A1
Gomez, JL1
Tremblay, RR3
Labrie, F1
Yücelten, D3
Gökmen, O1
Senöz, S1
Gülekli, B1
Işik, AZ1
Zemtsov, A1
Wilson, L1
Carmina, E2
Young, R1
Sinclair, R1
Moghetti, P3
Castello, R3
Zamberlan, N1
Rossini, M1
Gatti, D1
Negri, C3
Tosi, F3
Muggeo, M3
Adami, S1
Rittmaster, RS2
Dorizzi, R1
Fortunato, A1
Spiazzi, GG1
Tosti, A1
Misciali, C1
Perrone, F1
Caputo, M1
Malinova, M1
Lisboa, KO1
Mattiello, S1
Lhullier, F1
Gregoriou, O1
Bakas, P1
Konidaris, S1
Papadias, K1
Mathiopoulos, D1
Creatsas, G1
Devoto, E1
Aravena, L1
Ríos, R1
Boisselle, A1
Jaeger, P1
Brunner, HR1
Turini, GA1
Jéquier, E1
Ferguson, RK1
Gavras, H1
Ober, KP1
Hennessy, JF1
Cunliffe, WJ3
Jurzyk, RS1
Spielvogel, RL1
Rose, LI3
Bassaw, B1
Maharaj, R1
Ali, A1
Roopnarinesingh, S1
Shaw, JC1
O'Brien, RC1
Cooper, ME1
Murray, RM1
Seeman, E1
Thomas, AK2
Jerums, G2
Crosby, PD1
Wild, RA1
Demers, LM1
Applebaum-Bowden, D1
Lenker, R1
Derksen, J1
Krulder, JW1
Redmond, GP1
Gidwani, GP1
Gupta, MK1
Bedocs, NM1
Parker, R1
Skibinski, C1
Bergfeld, W1
Pugeat, M1
Elmidani, M1
Dechaud, H1
Garoscio-Cholet, M1
Lejeune, H1
Tourniaire, J1
Sciarra, F1
Toscano, V1
Concolino, G1
Di Silverio, F1
Adashi, EY1
McKenna, KM1
Pepperell, RJ1
Evans, J1
Prezelj, J1
Kocijancic, A1
Andolsek, L1
McLellan, AR1
Rentoul, J1
MacKie, R1
McInnes, GT1
Barth, JH1
Cherry, CA1
Wojnarowska, F1
Dawber, RP1
Nakajima, ST1
Brumsted, JR1
Riddick, DH1
Gibson, M2
Slobodniuk, R1
Taft, J1
Cooper, M1
Montalto, J1
Komarov, EK1
Svechnikova, FA1
Khrustaleva, GF1
Schmidt, JB1
Young, RL1
Goldzieher, JW1
Elkind-Hirsch, K1
Hughes, BR1
Reed, MJ1
Franks, S1
Callan, AW1
Serafini, P2
Köksal, A1
Pabuçcu, R1
Akyürek, C1
Burke, BM1
Kvedar, JC1
Krusinski, PA1
Pittaway, DE1
Maxson, WS1
Wentz, AC1
Anttila, L1
Ruutiainen, K1
Erkkola, R1
Helfer, EL2
Miller, JL1
Board, JA1
Rosenberg, SM1
Smeltzer, JS1
Siegberg, R1
Laatikainen, T1
Pelkonen, R1
Stenman, UH1
Lunde, O1
Djøseland, O1
Samojlik, E1
Szmal, E1
Moore, DC1
Chapman, MG2
Katz, M1
Dowsett, M2
Hague, W1
Jeffcoate, SL2
Dewhurst, CJ2
Evans, DJ1
Burke, CW1
Buckshee, K1
Ahuja, MM1
Morris, DV1
Guillebaud, J1
Brinton, D1
Horton, R1
Givens, JR1
Serafini, PC1
Catalino, J1
Manni, A1
Pardridge, WM1
Cefalu, W1
Nisula, BC1
Bardin, CW1
Santner, SJ1
Santen, RJ1
Dorrington-Ward, P1
McCartney, AC1
Holland, S1
Scully, J1
Carter, G1
Alaghband-Zadeh, J1
Wise, P1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616]56 participants (Actual)Interventional2010-05-31Completed
Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life[NCT05775328]39 participants (Anticipated)Observational2023-12-01Not yet recruiting
17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study[NCT01372293]49 participants (Actual)Interventional2005-01-31Completed
Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679]Phase 430 participants (Actual)Interventional2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

36 reviews available for spironolactone and Hirsutism

ArticleYear
Spironolactone in dermatology.
    Dermatologic therapy, 2022, Volume: 35, Issue:5

    Topics: Acne Vulgaris; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironolactone

2022
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
    JAMA dermatology, 2022, Mar-01, Volume: 158, Issue:3

    Topics: Acne Vulgaris; Aged; Breast Neoplasms; Female; Hirsutism; Humans; Male; Middle Aged; Prostatic Neopl

2022
Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis.
    Current pharmaceutical design, 2023, Volume: 29, Issue:19

    Topics: Androgen Antagonists; Female; Finasteride; Hirsutism; Humans; Polycystic Ovary Syndrome; Spironolact

2023
Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Drug-Related Side Effects and Adverse Reactions; Female; Follicle Stimulating Hormone, Human; Hirsut

2023
Spironolactone in dermatology: uses in acne and beyond.
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:8

    Topics: Acne Vulgaris; Adult; Alopecia; Dermatology; Drug Monitoring; Female; Hidradenitis Suppurativa; Hirs

2020
Androgens in women: Hormone-modulating therapies for skin disease.
    Journal of the American Academy of Dermatology, 2019, Volume: 80, Issue:6

    Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant

2019
Hirsutism in Women.
    American family physician, 2019, 08-01, Volume: 100, Issue:3

    Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv

2019
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C

2014
Interventions for hirsutism (excluding laser and photoepilation therapy alone).
    The Cochrane database of systematic reviews, 2015, Apr-28, Issue:4

    Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Fe

2015
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
    The British journal of dermatology, 2016, Volume: 175, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora

2016
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    The Cochrane database of systematic reviews, 2009, Apr-15, Issue:2

    Topics: Acne Vulgaris; Androgen Antagonists; Drug Therapy, Combination; Female; Hirsutism; Humans; Randomize

2009
Anti-androgen treatments.
    Annales d'endocrinologie, 2010, Volume: 71, Issue:1

    Topics: Androgen Antagonists; Cyproterone Acetate; Estrogens; Female; Finasteride; Flutamide; Gonadotropin-R

2010
Best methods for identification and treatment of PCOS.
    Minerva ginecologica, 2010, Volume: 62, Issue:1

    Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential

2010
Hirsutism: Diagnosis and management.
    Gender medicine, 2010, Volume: 7, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag

2010
Medical Treatment of Hirsutism in Women
    Current medicinal chemistry, 2010, Volume: 17, Issue:23

    Topics: Androgen Antagonists; Contraceptives, Oral; Cyproterone Acetate; Estrogens; Female; Hair Removal; Hi

2010
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    The Cochrane database of systematic reviews, 2003, Issue:4

    Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo

2003
Medical treatment regimens of hirsutism.
    Reproductive biomedicine online, 2004, Volume: 8, Issue:5

    Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol;

2004
Polycystic ovary syndrome.
    Clinical evidence, 2004, Issue:12

    Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin

2004
Spironolactone for hirsutism in polycystic ovary syndrome.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9

    Topics: Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spiron

2005
A systematic review of commonly used medical treatments for hirsutism in women.
    Clinical endocrinology, 2008, Volume: 68, Issue:5

    Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination

2008
[Hirsutism].
    Nederlands tijdschrift voor geneeskunde, 2007, Oct-20, Volume: 151, Issue:42

    Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone Acetate; Female; Hirsutism; Human

2007
Female hirsutism: pathophysiological considerations and therapeutic implications.
    Endocrine reviews, 1984,Fall, Volume: 5, Issue:4

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenal Glands; Adrenocorticotropic Hormone; Androgen Antagon

1984
Hirsutism.
    Archives of dermatology, 1983, Volume: 119, Issue:4

    Topics: 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Androgen Antagonists; And

1983
Hirsutism and the effectiveness of spironolactone in its management.
    Journal of endocrinological investigation, 1993, Volume: 16, Issue:11

    Topics: Androgen Antagonists; Clinical Trials as Topic; Hirsutism; Humans; Spironolactone

1993
Hirsutes. II: Treatment.
    The Australasian journal of dermatology, 1998, Volume: 39, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Contraceptives, O

1998
Antiandrogen treatment of polycystic ovary syndrome.
    Endocrinology and metabolism clinics of North America, 1999, Volume: 28, Issue:2

    Topics: Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirs

1999
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo

2000
Hirsutism: diagnosis and management.
    The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia, 2001, Volume: 4, Issue:2

    Topics: Adrenal Hyperplasia, Congenital; Androgens; Contraceptives, Oral; Eflornithine; Enzyme Inhibitors; F

2001
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    The Cochrane database of systematic reviews, 2001, Issue:4

    Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo

2001
Spironolactone in dermatologic therapy.
    Journal of the American Academy of Dermatology, 1991, Volume: 24, Issue:2 Pt 1

    Topics: Acne Vulgaris; Animals; Endocrine Glands; Hirsutism; Humans; Skin Diseases; Spironolactone

1991
Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.
    Fertility and sterility, 1990, Volume: 53, Issue:5

    Topics: Androgen Antagonists; Androgens; Biomechanical Phenomena; Contraceptives, Oral; Drug Therapy, Combin

1990
Treatment of hirsutism with spironolactone.
    Clinics in endocrinology and metabolism, 1986, Volume: 15, Issue:2

    Topics: 17-alpha-Hydroxyprogesterone; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Hirsut

1986
Anti-androgens in gynaecological practice.
    Bailliere's clinical obstetrics and gynaecology, 1988, Volume: 2, Issue:3

    Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Cyproterone; Female; Hirsutism; Humans; Spironolacto

1988
Spironolactone therapy in hirsutism and acne.
    The Australasian journal of dermatology, 1988, Volume: 29, Issue:3

    Topics: Acne Vulgaris; Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Recurrence; Spiro

1988
Hirsutism: evaluation and treatment.
    Journal of the American Academy of Dermatology, 1985, Volume: 12, Issue:2 Pt 1

    Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dexamethasone; Dihydrotestosterone; Female; Hair Remov

1985
Hirsutism.
    Clinics in obstetrics and gynaecology, 1985, Volume: 12, Issue:3

    Topics: Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenocortical Hyperfunction; Androgens; Cimetidine

1985

Trials

40 trials available for spironolactone and Hirsutism

ArticleYear
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2017, Volume: 61, Issue:4

    Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F

2017
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
    European journal of endocrinology, 2017, Volume: 177, Issue:5

    Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo

2017
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:2

    Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism;

2014
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com

2016
Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    The Journal of dermatological treatment, 2012, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Androgen Antagonists; Androstenes; Contraceptives, Oral, Combined; Cyproterone Ac

2012
17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:8

    Topics: 3-Hydroxysteroid Dehydrogenases; Adolescent; Adult; Aldo-Keto Reductase Family 1 Member C3; Brazil;

2012
Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
    Fertility and sterility, 2003, Volume: 79, Issue:4

    Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgen Antagonists; Androstenedione; Cyproterone

2003
Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.
    Acta medica Okayama, 2003, Volume: 57, Issue:2

    Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol;

2003
A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
    European journal of endocrinology, 2004, Volume: 150, Issue:3

    Topics: Adult; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finaste

2004
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
    Fertility and sterility, 2005, Volume: 84, Issue:6

    Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Diuretics; Drug Combinations; Drug Therapy, Combin

2005
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Advances in therapy, 2008, Volume: 25, Issue:4

    Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethi

2008
Antiandrogens in the treatment of acne and hirsutism.
    Journal of steroid biochemistry, 1983, Volume: 19, Issue:1B

    Topics: Acne Vulgaris; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Dru

1983
Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.
    Journal of endocrinological investigation, 1983, Volume: 6, Issue:1

    Topics: Adult; Androgen Antagonists; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Ho

1983
The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.
    Journal of endocrinological investigation, 1995, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Body Weight; Dehydroepiandrosterone; Estradiol; Female; Hirsutism; Hormone Antago

1995
A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:1

    Topics: Adolescent; Adult; Female; Finasteride; Hair; Hirsutism; Hormones; Humans; Prospective Studies; Spir

1995
Efficacy of flutamide versus spironolactone.
    Fertility and sterility, 1995, Volume: 63, Issue:3

    Topics: Contraceptives, Oral; Female; Flutamide; Hirsutism; Humans; Incidence; Menstruation Disturbances; Sp

1995
Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
    Acta Universitatis Palackianae Olomucensis Facultatis Medicae, 1993, Volume: 135

    Topics: Adolescent; Adult; Female; Hirsutism; Humans; Hyperandrogenism; Infant, Newborn; Luteinizing Hormone

1993
Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.
    Fertility and sterility, 1994, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Flutamide; Follic

1994
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.
    Fertility and sterility, 1994, Volume: 61, Issue:2

    Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Flutamide; Follicl

1994
Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Fertility and sterility, 1996, Volume: 66, Issue:2

    Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Contraceptives, Oral, Synthetic; Cyproterone Acetat

1996
Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1996, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Androgen Antagonists; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Contrac

1996
Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism.
    Fertility and sterility, 1997, Volume: 68, Issue:6

    Topics: Adult; Drug Administration Schedule; Enzyme Inhibitors; Female; Finasteride; Gonadal Steroid Hormone

1997
Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism.
    Fertility and sterility, 1998, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Cyproterone Acetate; Drug Combinations; Estradiol Congeners; Ethinyl Estradiol; F

1998
The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission.
    Fertility and sterility, 1998, Volume: 69, Issue:6

    Topics: Adult; Androgen Antagonists; Cohort Studies; Dexamethasone; Drug Combinations; Female; Follow-Up Stu

1998
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
    The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:4

    Topics: Adult; Bone and Bones; Bone Density; Bone Resorption; Female; Flutamide; Hirsutism; Humans; Polycyst

1999
Recurrence rate of hirsutism after 3 different antiandrogen therapies.
    Journal of the American Academy of Dermatology, 1999, Volume: 41, Issue:1

    Topics: Androgen Antagonists; Contraceptives, Oral; Cyproterone; Female; Flutamide; Hirsutism; Humans; Lutei

1999
Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.
    The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:1

    Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Biomarkers; Double-Blind Method; Enzym

2000
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
    The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:1

    Topics: Adult; Androgen Antagonists; Double-Blind Method; Female; Finasteride; Flutamide; Hair; Hirsutism; H

2000
[The treatment of hirsutism in adolescent girls with spironolactone].
    Akusherstvo i ginekologiia, 1999, Volume: 38, Issue:4

    Topics: Adolescent; Androgen Antagonists; Female; Hirsutism; Humans; Menstrual Cycle; Spironolactone; Time F

1999
Spironolactone as a single agent for long-term therapy of hirsute patients.
    Clinical endocrinology, 2000, Volume: 52, Issue:5

    Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Cyproterone Acetate; Drug Therapy, Combina

2000
The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2000, Volume: 14, Issue:5

    Topics: Adult; Alkaline Phosphatase; Bone Density; Calcium; Contraceptives, Oral, Combined; Desogestrel; Dru

2000
[Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone].
    Revista medica de Chile, 2000, Volume: 128, Issue:8

    Topics: Adolescent; Adult; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocortico

2000
Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 72, Issue:5

    Topics: Adult; Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone; Cyproterone Acetate; Drug

1991
Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Contraception, 1991, Volume: 44, Issue:2

    Topics: Analysis of Variance; Androstane-3,17-diol; Blood Pressure; Body Weight; Cholesterol, HDL; Ethinyl E

1991
Antiandrogens: clinical applications.
    The Journal of steroid biochemistry and molecular biology, 1990, Nov-20, Volume: 37, Issue:3

    Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic

1990
Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1989, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Androgens; Dexamethasone; Drug Therapy, Combination; Estrogens; Female; Follicle

1989
Lack of effect of spironolactone on hair shaft diameter in hirsute females.
    Postgraduate medical journal, 1989, Volume: 65, Issue:765

    Topics: Androgens; Canrenone; Double-Blind Method; Female; Gonadotropins, Pituitary; Hair; Hirsutism; Humans

1989
Antiandrogens and hirsutism.
    Hormone research, 1987, Volume: 28, Issue:2-4

    Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cy

1987
Spironolactone in the treatment of hirsutism.
    Annales chirurgiae et gynaecologiae. Supplementum, 1987, Volume: 202

    Topics: Adult; Androgens; Clinical Trials as Topic; Female; Hair; Hirsutism; Humans; Sex Hormone-Binding Glo

1987
Endocrine and clinical effects of spironolactone in female hyperandrogenism.
    Archives of gynecology, 1987, Volume: 240, Issue:2

    Topics: Adult; Amenorrhea; Androgens; Double-Blind Method; Endocrine System Diseases; Female; Gonadotropins,

1987

Other Studies

84 other studies available for spironolactone and Hirsutism

ArticleYear
Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism:
    Drug delivery, 2021, Volume: 28, Issue:1

    Topics: Administration, Topical; Androgen Antagonists; Animals; Ceramides; Chemistry, Pharmaceutical; Drug C

2021
Female Pelvic Conditions: Polycystic Ovary Syndrome.
    FP essentials, 2022, Volume: 515

    Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans;

2022
Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders.
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:2

    Topics: Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Polycystic Ovary Syndrome; Quality of Life; R

2023
[Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life].
    Gynecologie, obstetrique, fertilite & senologie, 2022, Volume: 50, Issue:9

    Topics: Contraceptives, Oral, Combined; Female; Hirsutism; Humans; Quality of Life; Retrospective Studies; S

2022
High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:3

    Topics: Acne Vulgaris; Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary S

2021
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.
    Actas dermo-sifiliograficas, 2020, Volume: 111, Issue:8

    Topics: Acne Vulgaris; Alopecia; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironola

2020
Spironolactone and breast cancer: Fear not!
    Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:4

    Topics: Breast Neoplasms; Fear; Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Retrospective Studies

2020
Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats.
    AAPS PharmSciTech, 2021, Jul-13, Volume: 22, Issue:5

    Topics: Animals; Drug Carriers; Drug Evaluation, Preclinical; Female; Hirsutism; Hydrogels; Inflammation; Na

2021
Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
    Journal of women's health (2002), 2018, Volume: 27, Issue:7

    Topics: Contraceptives, Oral; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hirsutism; Humans;

2018
Hirsutism - from diagnosis to use of antiandrogens.
    Frontiers of hormone research, 2013, Volume: 40

    Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H

2013
[Treatment of hirsutism].
    Praxis, 2009, Sep-09, Volume: 98, Issue:18

    Topics: Adult; Androgen Antagonists; Contraceptives, Oral, Combined; Diagnosis, Differential; Evidence-Based

2009
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:4

    Topics: Adolescent; Adult; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Hirsutism; Humans; Lipids; Min

2009
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem

2012
Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
    Gynecologic and obstetric investigation, 2012, Volume: 74, Issue:2

    Topics: Adult; Androgens; Anovulation; Aromatase; Blood Pressure; Body Mass Index; Contraceptives, Oral; Eth

2012
Pneumomediastinum after retching.
    BMJ case reports, 2012, Oct-10, Volume: 2012

    Topics: Adult; Female; Hirsutism; Humans; Mediastinal Emphysema; Mineralocorticoid Receptor Antagonists; Rad

2012
From HAIR-AN to eternity.
    Journal of pediatric and adolescent gynecology, 2002, Volume: 15, Issue:4

    Topics: Acanthosis Nigricans; Child; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Polycy

2002
Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
    Fertility and sterility, 2002, Volume: 78, Issue:6

    Topics: Adult; Androgen Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finasteride; Hirs

2002
The treatment of polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate;

2004
High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2004, Volume: 19, Issue:4

    Topics: 17-alpha-Hydroxyprogesterone; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Dehydroepian

2004
Assessment, diagnosis and treatment of a patient with hirsutism.
    Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:5

    Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Ethinyl Estradiol; Female; Hirsutism; Humans; Poly

2008
[Indications and limits of anti-androgen therapy].
    Zeitschrift fur Hautkrankheiten, 1984, Aug-15, Volume: 59, Issue:16

    Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Cyproterone Aceta

1984
[Therapy of female hirsutism: current status and new findings].
    La Clinica terapeutica, 1983, Mar-31, Volume: 104, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Bromocrip

1983
[Cyproterone acetate and spironolactone compared in the therapy of female hirsutism].
    La Clinica terapeutica, 1983, Mar-31, Volume: 104, Issue:6

    Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Drug

1983
The influence of androgens on insulin resistance.
    Fertility and sterility, 1984, Volume: 41, Issue:3

    Topics: Adult; Androgens; Androstane-3,17-diol; Dehydroepiandrosterone; Dihydrotestosterone; Female; Hirsuti

1984
[Hormonotherapy in acute, idiopathic hirsutism, and seborrheic alopecia (author's transl)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1982, Jul-01, Volume: 58, Issue:26-27

    Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Dermatitis, Seborrheic; Estro

1982
Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
    Clinical and experimental obstetrics & gynecology, 1984, Volume: 11, Issue:1-2

    Topics: 17-Ketosteroids; Adolescent; Adult; Estradiol; Female; Follicle Stimulating Hormone; Hirsutism; Huma

1984
[Spironolactone in idiopathic hirsutism, clinical and biological evaluation of treatment].
    Annales d'endocrinologie, 1983, Volume: 44, Issue:6

    Topics: Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Hormone; Spironolactone;

1983
[Diagnosis and treatment of hirsutism].
    Duodecim; laaketieteellinen aikakauskirja, 1984, Volume: 100, Issue:11

    Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dexamethasone; Drug Combinations; Ethinyl Es

1984
[Long-term treatment of hirsutism with spirolactone].
    Casopis lekaru ceskych, 1984, Oct-19, Volume: 123, Issue:42

    Topics: Adult; Hirsutism; Humans; Male; Spironolactone

1984
Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
    Fertility and sterility, 1981, Volume: 36, Issue:4

    Topics: 17-Ketosteroids; Androgens; Anovulation; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Lu

1981
Therapeutic effects of spironolactone in polycystic ovary syndrome.
    Obstetrics and gynecology, 1983, Volume: 61, Issue:4

    Topics: Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Pituitary Hormones; Polycystic Ovary Sy

1983
Treatment of idiopathic hirsutism with spironolactone.
    Dermatologica, 1982, Volume: 165, Issue:3

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hirsutism; Humans; Middle

1982
Hirsutism and problem of its management.
    Indian journal of dermatology, 1982, Volume: 27, Issue:2

    Topics: Adolescent; Adult; Allylestrenol; Dexamethasone; Ethinyl Estradiol; Female; Hirsutism; Humans; Polyc

1982
[Results of treatment of hirsutism with spironolactone].
    Endokrynologia Polska, 1982, Volume: 33, Issue:1-3

    Topics: Adult; Androgen Antagonists; Female; Hirsutism; Humans; Luteinizing Hormone; Spironolactone; Testost

1982
Treatment of hirsutism with spironolactone.
    JAMA, 1982, Mar-05, Volume: 247, Issue:9

    Topics: Amenorrhea; Androgen Antagonists; Androgens; Androstenedione; Cytochrome P-450 Enzyme Inhibitors; Fa

1982
Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine.
    Obstetrics and gynecology, 1981, Volume: 57, Issue:5

    Topics: Adult; Bromocriptine; Female; Hirsutism; Hormones; Humans; Hypertension; Polycystic Ovary Syndrome;

1981
Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome.
    Fertility and sterility, 1981, Volume: 35, Issue:6

    Topics: Adult; Blood Pressure; Body Weight; Bromocriptine; Drug Therapy, Combination; Female; Glucose Tolera

1981
Tumorigenic aspect of spironolactone.
    The Western journal of medicine, 1981, Volume: 135, Issue:3

    Topics: Hirsutism; Humans; Neoplasms; Spironolactone

1981
[Can the anti-androgenic effect of spironolactone contraindicate its use in pregnancy?].
    Minerva ginecologica, 1980, Volume: 32, Issue:4

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Animals; Female; Fetus; Genitalia, Male; Hirsutism;

1980
A novel use of spironolactone: treatment of hirsutism.
    The Journal of clinical endocrinology and metabolism, 1980, Volume: 51, Issue:3

    Topics: Adolescent; Adult; Androgen Antagonists; Estradiol; Female; Hirsutism; Humans; Menstruation; Spirono

1980
[Can the anti-androgenic effect of spironolactone contraindicate its use in pregnancy?].
    Minerva medica, 1980, Oct-13, Volume: 71, Issue:39

    Topics: Abnormalities, Drug-Induced; Androgen Antagonists; Androgens; Animals; Female; Fetus; Genitalia, Mal

1980
Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.
    Archives of dermatology, 1997, Volume: 133, Issue:4

    Topics: Acanthosis Nigricans; Adolescent; Androgen Antagonists; Contraceptives, Oral, Combined; Contraceptiv

1997
Diane 35 and spironolactone combination in the treatment of hirsutism.
    Clinical endocrinology, 2001, Volume: 54, Issue:5

    Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism;

2001
New therapeutic approach to the hirsute patient.
    Fertility and sterility, 1979, Volume: 32, Issue:3

    Topics: 17-Ketosteroids; Adolescent; Adult; Child; Female; Hair; Hirsutism; Humans; Receptors, Androgen; Spi

1979
[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers].
    Schweizerische medizinische Wochenschrift, 1978, Nov-04, Volume: 108, Issue:44

    Topics: Adult; Aldosterone; Chlorthalidone; Female; Furosemide; Hirsutism; Humans; Hypertension; Male; Middl

1978
Spironolactone therapy for hirsutism in a hyperandrogenic woman.
    Annals of internal medicine, 1978, Volume: 89, Issue:5 Pt 1

    Topics: Adult; Androgens; Female; Hirsutism; Humans; Hypertension; Spironolactone

1978
Spironolactone in dermatology.
    Journal of the American Academy of Dermatology, 1992, Volume: 26, Issue:1

    Topics: Acne Vulgaris; Female; Hirsutism; Humans; Spironolactone

1992
Antiandrogens in the treatment of acne and hirsutism.
    American family physician, 1992, Volume: 45, Issue:4

    Topics: Acne Vulgaris; Cyproterone; Hirsutism; Humans; Spironolactone

1992
Therapeutic alternatives for the hirsute woman.
    The West Indian medical journal, 1992, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination

1992
Predictors of clinical response in hirsute women treated with spironolactone.
    Fertility and sterility, 1991, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Age Factors; Body Mass Index; Child; Contraceptives, Oral; Dehydroepiandrosterone

1991
Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
    Obstetrics and gynecology, 1991, Volume: 78, Issue:5 Pt 1

    Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Androster

1991
Spironolactone for porphyria cutanea tarda associated hirsutism.
    Lancet (London, England), 1990, May-05, Volume: 335, Issue:8697

    Topics: Adult; Female; Hirsutism; Humans; Porphyrias; Severity of Illness Index; Spironolactone

1990
Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
    Journal of the American Academy of Dermatology, 1990, Volume: 22, Issue:1

    Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate;

1990
[Treatment of hirsutism with spironolactone and progestagen combination].
    Presse medicale (Paris, France : 1983), 1990, Oct-13, Volume: 19, Issue:33

    Topics: Acne Vulgaris; Adolescent; Adult; Drug Therapy, Combination; Female; Hirsutism; Humans; Norprogester

1990
Use of spironolactone in treatment of hirsutism.
    Cleveland Clinic journal of medicine, 1990, Volume: 57, Issue:3

    Topics: Contraceptives, Oral; Dexamethasone; Drug Therapy, Combination; Female; Hirsutism; Humans; Spironola

1990
Hirsutism in a gynaecological context.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1990, Volume: 30, Issue:2

    Topics: Adult; Anovulation; Contraceptives, Oral, Hormonal; Female; Gonadal Steroid Hormones; Hirsutism; Hum

1990
Hirsutism--a low dose spironolactone therapy.
    Acta Universitatis Palackianae Olomucensis Facultatis Medicae, 1989, Volume: 122

    Topics: Adolescent; Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Hormone; Spi

1989
Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women.
    The Journal of clinical endocrinology and metabolism, 1989, Volume: 68, Issue:5

    Topics: Adult; Androgen Antagonists; Drug Tolerance; Female; Hair; Hirsutism; Humans; Menstrual Cycle; Spiro

1989
Absence of progestational activity of oral spironolactone.
    Fertility and sterility, 1989, Volume: 52, Issue:1

    Topics: Endometrium; Estrogens; Female; Hirsutism; Humans; Menstruation Disturbances; Progesterone; Prolacti

1989
The treatment of hirsutism: experience with cyproterone acetate and spironolactone.
    The Australasian journal of dermatology, 1985, Volume: 26, Issue:1

    Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Female; Hirsutism; Humans; Spironolactone; T

1985
[State of the hypothalamo-hypophyseo-ovarian function in patients with hyperandrogenemia during treatment with spironolactone].
    Akusherstvo i ginekologiia, 1985, Issue:9

    Topics: Adult; Female; Hirsutism; Humans; Hypothalamo-Hypophyseal System; Ovary; Spironolactone; Testosteron

1985
[The concept of the causal therapy of hirsutism].
    Zeitschrift fur Hautkrankheiten, 1986, Feb-15, Volume: 61, Issue:4

    Topics: Cimetidine; Cyproterone; Cyproterone Acetate; Hirsutism; Humans; Medroxyprogesterone; Medroxyprogest

1986
The endocrine effects of spironolactone used as an antiandrogen.
    Fertility and sterility, 1987, Volume: 48, Issue:2

    Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Femal

1987
Tolerance of spironolactone.
    The British journal of dermatology, 1988, Volume: 118, Issue:5

    Topics: Acne Vulgaris; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Tolerance; Female; Hirsutism;

1988
The effects of spironolactone on adrenal steroidogenesis in hirsute women.
    Fertility and sterility, 1985, Volume: 44, Issue:5

    Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Androst

1985
Spironolactone in the treatment of hirsutism.
    Archives of gynecology, 1987, Volume: 240, Issue:2

    Topics: 17-Ketosteroids; Adolescent; Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Spirono

1987
Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
    The British journal of dermatology, 1985, Volume: 112, Issue:1

    Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Female; Hirsutism; Humans; Spironolactone

1985
Spironolactone in combination drug therapy for unresponsive hirsutism.
    Fertility and sterility, 1985, Volume: 43, Issue:6

    Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Drug Th

1985
Side-effects of spironolactone therapy in the hirsute woman.
    The Journal of clinical endocrinology and metabolism, 1988, Volume: 66, Issue:1

    Topics: Adult; Alopecia; Female; Hirsutism; Humans; Menstrual Cycle; Metrorrhagia; Spironolactone; Testoster

1988
Spironolactone and estrogen-progestin therapy for hirsutism.
    Southern medical journal, 1987, Volume: 80, Issue:4

    Topics: Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Ethinyl Estradiol; Female;

1987
Drug therapy for hirsutism.
    American family physician, 1987, Volume: 36, Issue:2

    Topics: Androgen Antagonists; Cyproterone; Estrogens; Female; Glucocorticoids; Hirsutism; Humans; Spironolac

1987
A comparative study of Aldactone and Diane in the treatment of hirsutism.
    Journal of steroid biochemistry, 1987, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Cyproterone; Cyproterone Acetate; Drug Combinations; Drug Evaluation; Ethinyl Est

1987
Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism.
    The Journal of clinical endocrinology and metabolism, 1987, Volume: 65, Issue:4

    Topics: Adolescent; Adult; Androstane-3,17-diol; Androstanols; Contraceptives, Oral, Combined; Contraceptive

1987
Prolonged suppression of hirsutism with combination therapy in an adolescent with insulin resistance and acanthosis nigricans.
    Journal of adolescent health care : official publication of the Society for Adolescent Medicine, 1987, Volume: 8, Issue:5

    Topics: Acanthosis Nigricans; Adolescent; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; H

1987
Spironolactone in the treatment of hirsutism.
    Acta obstetricia et gynecologica Scandinavica, 1986, Volume: 65, Issue:4

    Topics: Female; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Hirsutism; Humans; Spironolactone

1986
Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.
    Journal of the Royal Society of Medicine, 1986, Volume: 79, Issue:8

    Topics: Adolescent; Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Middle Aged; Polycystic Ova

1986
Therapeutic evaluation of spironolactone in Indian women with hirsutism.
    The Journal of the Association of Physicians of India, 1986, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Drug Therapy, Combination; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combin

1986
Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
    British journal of obstetrics and gynaecology, 1986, Volume: 93, Issue:2

    Topics: Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Hirsutism; Humans; Spironolactone

1986
The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
    Fertility and sterility, 1985, Volume: 43, Issue:2

    Topics: Adult; Androgen Antagonists; Androgens; Dose-Response Relationship, Drug; Female; Hair; Hirsutism; H

1985
Treatment of hirsutism with spironolactone.
    Fertility and sterility, 1985, Volume: 43, Issue:6

    Topics: Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Menstruation Disturbances; Spiro

1985
The effect of spironolactone on genital skin 5 alpha-reductase activity.
    Journal of steroid biochemistry, 1985, Volume: 23, Issue:2

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adult; Female; Hirsutism; Humans; Kinetics; Oxidoreductases;

1985
Bioavailability of albumin-bound testosterone.
    The Journal of clinical endocrinology and metabolism, 1985, Volume: 61, Issue:4

    Topics: Adult; Biological Availability; Brain; Carotid Arteries; Computers; Female; Hirsutism; Humans; Injec

1985
Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
    British journal of obstetrics and gynaecology, 1985, Volume: 92, Issue:9

    Topics: Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Combinations; Drug Therapy, Com

1985
The effect of spironolactone on hirsutism and female androgen metabolism.
    Clinical endocrinology, 1985, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Androgen Antagonists; Female; Hair; Hirsutism; Humans; Spironolactone; Testostero

1985